Heng Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Heng Liu has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Chongyuan Wang
Center for Human Tissues and Organs Degeneration, Faculty of Pharmaceutical Sciences, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China
2 shared publications Fumei Zhong
The Affiliated Traditional Chinese Medicine Hospital, GMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macao Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Disease, State Key Laboratory of Respiratory Disease, Guangzhou, China
2 shared publicationsJiawei Li
Department of Geriatric Medicine, Shenzhen Longhua District Central Hospital, Shenzhen, China
2 shared publicationsLimin Zhao
Department of Geriatric Medicine, Shenzhen Longhua District Central Hospital, Shenzhen, China
2 shared publicationsMiaofang Xiao
The Affiliated Traditional Chinese Medicine Hospital, GMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macao Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Disease, State Key Laboratory of Respiratory Disease, Guangzhou, China
2 shared publicationsMu Li
The Affiliated Traditional Chinese Medicine Hospital, GMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macao Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Disease, State Key Laboratory of Respiratory Disease, Guangzhou, China
2 shared publications
Latest Publications
- Open Access
- 30 January 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Structural analysis reveals that water molecules mediate self-activation of GPR99
GPR99 holds promise as a potential therapeutic target for inflammatory diseases. GPR99 exhibits marked basal activity when coupled with the G q protein, its activation mechanism remains elusive. In this study, we determine the high-resolution structure of the human GPR99 in complex with the heterotrimeric miniG q in the ligand-free state using cryo-electron microscopy (cryo-EM). Our structural analysis and functional experiments reveal that the second extracellular loop (ECL2) of GPR99 occupies the orthosteric binding pocket, thereby promoting receptor self-activation. Moreover, we observe structural water molecules forming an extended polar network that connects ECL2 and the binding pocket, intricately linking these elements to the receptor’s functional activity. Structure-based mutagenesis experiments further validate the critical role of ECL2 in intracellular signal transduction of GPR99, offering a structural basis for exploring its function under physiological or pathological conditions. Additionally, these findings also provide a crucial theoretical framework for the design of drugs targeting GPR99.
- 30 January 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Open AccessStructural analysis reveals that water molecules mediate self-activation of GPR99
GPR99 holds promise as a potential therapeutic target for inflammatory diseases. GPR99 exhibits marked basal activity when coupled with the G q protein, its activation mechanism remains elusive. In this study, we determine the high-resolution structure of the human GPR99 in complex with the heterotrimeric miniG q in the ligand-free state using cryo-electron microscopy (cryo-EM). Our structural analysis and functional experiments reveal that the second extracellular loop (ECL2) of GPR99 occupies the orthosteric binding pocket, thereby promoting receptor self-activation. Moreover, we observe structural water molecules forming an extended polar network that connects ECL2 and the binding pocket, intricately linking these elements to the receptor’s functional activity. Structure-based mutagenesis experiments further validate the critical role of ECL2 in intracellular signal transduction of GPR99, offering a structural basis for exploring its function under physiological or pathological conditions. Additionally, these findings also provide a crucial theoretical framework for the design of drugs targeting GPR99.
- Open Access
- 16 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Molecular insights into ago-allosteric modulation at cysteinyl leukotriene receptor 2
Cysteinyl leukotriene receptor CysLT2R, which is activated by the endogenous cysteinyl leukotrienes (CysLTs) LTC4, LTD4, and LTE4, has emerged as a potential therapeutic target due to the involvement in various inflammatory diseases. Accumulating evidence indicates that CysLT2R is also involved in the pathogenesis of cardiovascular diseases and contribute to tumor progression in cancer. However, the structural basis underlying the ligand recognition and the receptor activation remains to be elucidated. Here, we present two cryo-electron microscopy (cryo-EM) structures of the human CysLT2R-G q complexes bound to LTC4 and LTD4. CysLTs are characterized as ago-allosteric modulators (ago-PAMs) of CysLT2R. Our structures reveal that CysLTs are recognized by a lipid-facing pocket above intracellular loop 2 (ICL2) near the cytoplasmic side of the receptor. Furthermore, a noncanonical activation mechanism exists between the allosteric binding pocket and the G q -binding site. Our findings provide comprehensive insights into the recognition of CysLTs and G q protein signaling transduction by CysLT2R, which may facilitate rational design of drugs.
- 16 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessMolecular insights into ago-allosteric modulation at cysteinyl leukotriene receptor 2
Cysteinyl leukotriene receptor CysLT2R, which is activated by the endogenous cysteinyl leukotrienes (CysLTs) LTC4, LTD4, and LTE4, has emerged as a potential therapeutic target due to the involvement in various inflammatory diseases. Accumulating evidence indicates that CysLT2R is also involved in the pathogenesis of cardiovascular diseases and contribute to tumor progression in cancer. However, the structural basis underlying the ligand recognition and the receptor activation remains to be elucidated. Here, we present two cryo-electron microscopy (cryo-EM) structures of the human CysLT2R-G q complexes bound to LTC4 and LTD4. CysLTs are characterized as ago-allosteric modulators (ago-PAMs) of CysLT2R. Our structures reveal that CysLTs are recognized by a lipid-facing pocket above intracellular loop 2 (ICL2) near the cytoplasmic side of the receptor. Furthermore, a noncanonical activation mechanism exists between the allosteric binding pocket and the G q -binding site. Our findings provide comprehensive insights into the recognition of CysLTs and G q protein signaling transduction by CysLT2R, which may facilitate rational design of drugs.
- Top Cited PapersOpen Access
- 18 December 2020
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 370 (6523) , 1479-1484
Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2
Nanobodies that neutralize: Monoclonal antibodies that bind to the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) show therapeutic promise but must be produced in mammalian cells and need to be delivered intravenously. By contrast, single-domain antibodies called nanobodies can be produced in bacteria or yeast, and their stability may enable aerosol delivery. Two papers now report nanobodies that bind tightly to spike and efficiently neutralize SARS-CoV-2 in cells. Schoof et al. screened a yeast surface display of synthetic nanobodies and Xiang et al. screened anti-spike nanobodies produced by a llama. Both groups identified highly potent nanobodies that lock the spike protein in an inactive conformation. Multivalent constructs of selected nanobodies achieved even more potent neutralization. Science , this issue p. 1473 , p. 1479
- 18 December 2020
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 370 (6523) , 1479-1484
Top Cited PapersOpen AccessVersatile and multivalent nanobodies efficiently neutralize SARS-CoV-2
Nanobodies that neutralize: Monoclonal antibodies that bind to the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) show therapeutic promise but must be produced in mammalian cells and need to be delivered intravenously. By contrast, single-domain antibodies called nanobodies can be produced in bacteria or yeast, and their stability may enable aerosol delivery. Two papers now report nanobodies that bind tightly to spike and efficiently neutralize SARS-CoV-2 in cells. Schoof et al. screened a yeast surface display of synthetic nanobodies and Xiang et al. screened anti-spike nanobodies produced by a llama. Both groups identified highly potent nanobodies that lock the spike protein in an inactive conformation. Multivalent constructs of selected nanobodies achieved even more potent neutralization. Science , this issue p. 1473 , p. 1479